NeoPhotonics (NPTN)’s CEO Timothy Jenks Sold 92,125 Shares, Navidea Biopharmaceuticals (NYSEMKT:NAVB) Has 0.72 Sentiment

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical firm focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company has market cap of $87.93 million. The Firm is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. It currently has negative earnings. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages.

CEO Timothy Jenks of Neophotonics Corp, sold 92,125 of the California-based company shares valued at near $677,202 U.S. Dollars with an average of $7.4 per share. Currently, Mr. Timothy, owns 258,144 shares, which accounts for 0.54% of the Company’s market cap. This sale, which was filled on 09-05-2017 was disclosed in a report with the (SEC).

The stock decreased 10.52% or $0.058 during the last trading session, reaching $0.492. About shares traded. Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) has declined 44.94% since October 3, 2016 and is downtrending. It has underperformed by 55.85% the S&P500.

Analysts await Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) to report earnings on May, 16.

Spark Investment Management Llc holds 0.02% of its portfolio in Navidea Biopharmaceuticals Inc for 420,000 shares. Bridgeway Capital Management Inc owns 649,880 shares or 0.01% of their US portfolio. Moreover, Lifeplan Financial Group Inc has 0.01% invested in the company for 28,810 shares. The New York-based Two Sigma Securities Llc has invested 0.01% in the stock. A.R.T. Advisors Llc, a New York-based fund reported 51,700 shares.

The stock increased 11.56% or $0.89 during the last trading session, reaching $8.59. About shares traded. NeoPhotonics Corp (NYSE:NPTN) has declined 46.71% since October 3, 2016 and is downtrending. It has underperformed by 57.62% the S&P500.

Investors sentiment decreased to 0.93 in Q4 2016. Its down 0.07, from 1 in 2016Q3. It dived, as 31 investors sold NeoPhotonics Corp shares while 39 reduced holdings. 22 funds opened positions while 43 raised stakes. 29.29 million shares or 5.97% more from 27.64 million shares in 2016Q3 were reported. Prelude Capital Mgmt Limited Liability Com holds 2,600 shares or 0% of its portfolio. California-based Schwab Charles Invest Mngmt has invested 0% in NeoPhotonics Corp (NYSE:NPTN). Marshall Wace Llp accumulated 56,750 shares. Panagora Asset Mngmt reported 20,290 shares. Alphaone Invest Svcs Limited Liability Co holds 404,727 shares or 1.21% of its portfolio. Bridgeway Cap Mgmt holds 0.01% of its portfolio in NeoPhotonics Corp (NYSE:NPTN) for 50,000 shares. Stoneridge Inv Partners Ltd Co reported 49,121 shares. Great West Life Assurance Can owns 0% invested in NeoPhotonics Corp (NYSE:NPTN) for 3,200 shares. State Common Retirement Fund has 0% invested in NeoPhotonics Corp (NYSE:NPTN) for 225,830 shares. Shell Asset has 66,565 shares. Envestnet Asset Management accumulated 2,747 shares. Blackrock Fund reported 0% of its portfolio in NeoPhotonics Corp (NYSE:NPTN). Morgan Stanley reported 0% stake. Blackrock Advsr reported 0% stake. Financial Bank Of America De has 124,285 shares for 0% of their portfolio.

NeoPhotonics Corporation develops, manufactures and markets optoelectronic products that transmit, receive and switch digital optical signals for communications networks. The company has market cap of $376.82 million. The Firm develops and makes Transmitter Products, Receiver Products and Switch Products that are used in ultra-high speed digital optical communications, high speed switching and provisioning, and access connections for wireless and fiber-to-the-home communications networks. It currently has negative earnings. The Company’s products are categorized into groups, including High Speed Products and Network Products and Solutions.

Among 7 analysts covering NeoPhotonics (NYSE:NPTN), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. NeoPhotonics has $24 highest and $8.75 lowest target. $11.44’s average target is 33.18% above currents $8.59 stock price. NeoPhotonics had 13 analyst reports since August 7, 2015 according to SRatingsIntel. Northland Capital maintained it with “Outperform” rating and $13 target in Monday, December 7 report. The firm has “Strong Buy” rating by Raymond James given on Wednesday, February 3. The stock of NeoPhotonics Corp (NYSE:NPTN) has “Strong Buy” rating given on Wednesday, March 15 by Needham. As per Monday, October 31, the company rating was maintained by Needham. Northland Capital initiated the stock with “Outperform” rating in Tuesday, August 18 report. The firm has “Outperform” rating given on Friday, November 6 by Raymond James. The firm has “Strong Buy” rating given on Tuesday, December 20 by Needham. Needham maintained the shares of NPTN in report on Monday, September 12 with “Strong Buy” rating. The rating was initiated by Piper Jaffray on Tuesday, February 23 with “Overweight”. The firm has “Outperform” rating by Raymond James given on Monday, August 10.